Thrombocytopenia resulted from the antitumor therapy of breast cancer
Conditions
Interventions
Herombopag Olamine group:Nil
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Men and women greater than or equal to 18 years of age; 2. Participants must have histologically or cytologically confirmed breast cancer; 3. Platelet count<50x10^9/L during the current anti-tumor treatment cycle, and could accept the current anti-tumor treatment plan for at least 1 cycle; 4. ECOG performance status 0-2; 5. Volunteer to join this study and sign an informed consent form; have good treatment compliance; 6. Sign an informed consent form to participate in the experimental treatment.
Exclusion criteria
Exclusion criteria: 1. Suffer from the following hematopoietic system diseases caused by tumor anti-tumor drugs other than thrombocytopenia , including but not limited to leukemia, primary immune thrombocytopenia, bone marrow proliferative diseases, multiple myeloma, and myelodysplastic syndromes, etc. 2. Thrombocytopenia caused by non-antitumor therapy in the 6 months before screening, including but not limited to chronic liver disease, hypersplenism, infection, and bleeding; 3. Bone marrow invasion or bone marrow metastasis; 4. Have received pelvic, spinal radiotherapy and osseous field irradiation within 3 months before screening, or are currently/expected to receive radiotherapy; 5. Have received thrombopoietin receptor agonists (such as eltrombopag, romiplostim), or recombinant human thrombopoietin(rhTPO), recombinant human interleukin-11 (rhIL-11) during the current anti-tumor treatment cycle )treatment; 6. Have received platelet transfusion within 3 days before screening 7. Those who have been confirmed to be allergic to Herombopag and/or its excipients; 8. Pregnant or breastfeeding women; 9. Patients who are participating in other clinical trials; 10. Doctors evaluate patients who are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelet count; | — |
Countries
China
Contacts
Public ContactGuo Zhaoji
the First Affiliated Hospital of Soochow University
Outcome results
None listed